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Abstract
We evaluated 800 hospitalized patients with a complicated urinary
tract infection, from whom both a blood and a urine culture were
obtained on the ﬁrst day of antibiotic treatment. Urine cultures
were positive in 70% of patients, and blood cultures were positive
in 29%. In 7% of patients, uropathogens caused bacteraemia with a
pathogen that was not isolated from urine. Receiving antibiotic
therapy at the moment of hospitalization was the only factor
independently associated with discordant culture results (OR,
2.06; 95% CI, 1.18–3.61). For those receiving antibiotics at the
moment of hospitalization, blood cultures have additional diag-
nostic value over urine cultures.
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Bacteraemia is present in 15–25% of patients with complicated
urinary tract infections (UTIs) [1]. In many UTI treatment
guidelines, collection of blood cultures is not recommended
[2–4], as they may provide little additional diagnostic value over
urine cultures [5–8]. In contrast, other authors recommend
collecting blood cultures from all patients with a complicated
UTI [9,10], or at least patients at risk of discordant culture
results (i.e. bacteraemia with uropathogens that could not be
cultured from urine) [11,12]. However, the risk factors for
discordant culture results are not unambiguous [11,12]. The
objective of the present study was to assess the rate of
discordant culture results, and to identify for which group of
patients collection of a blood culture seems useful.
We conducted a retrospective observational cohort study,
which was part of the baseline measurement of a cluster-ran-
domized trial testing a multifaceted antibiotic stewardship
programme in patients with a complicated UTI. The details have
been described before [13]. Brieﬂy, the departments of internal
medicine and urology of 19 hospitals located throughout the
Netherlands participated. Included were adult inpatients/out-
patients diagnosed with a complicated UTI, including uncom-
plicated pyelonephritis [13,14], who started antibiotic therapy.
For the present study, we only considered those hospitalized
patients for whom both a blood culture and a urine culture
were obtained on ﬁrst day of antibiotic treatment. In case a
patient was admitted after 21.00, a urine culture obtained the
next day was also accepted. The ethics committee deemed the
study exempt from their approval.
Blood and urine cultures were considered ‘positive’ when a
bacterial pathogen was regarded as pathogenic (at least 10E4
or 10E5 cfu/mL) by the attending microbiologist and reported
together with a susceptibility pattern. Contamination was
deﬁned as culture results that were regarded and reported as
‘contaminated’ by the attending microbiologist, or a urine
culture that revealed growth of at least three bacterial species.
Coagulase-negative staphylococci isolated from a blood cul-
ture were also considered to represent contamination.
Contaminated cultures were included in the analysis. A culture
was deﬁned as ‘sterile’ when it did not show any bacterial
growth or when a bacterial pathogen was regarded as low
pathogenic by the attending microbiologist.
Concurrent blood and urine cultures could be either
discordant or concordant. A discordant culture result was
deﬁned as a positive blood culture with a related urine culture
that showed growth of another microorganism, did not show
bacterial growth, or was contaminated. In the case of
discordant culture results a blood culture was considered to
have ‘additional value’ over a urine culture. A concordant
culture result was deﬁned as a positive urine culture with a
related blood culture that showed growth of the same
microorganism, showed no growth, or was contaminated.
Concurrent sterile or contaminated blood and urine culture
results were considered ‘concordant’ as well. In the case of
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concordant culture results a blood culture was considered to
have ‘no additional value’.
Of 1314 patients with a complicated UTI, 514 were
excluded, mainly because blood and/or urine cultures had
not been performed, but 800 were included (Fig. 1). Baseline
characteristics are listed in Table 1.
The urine culture results showed one pathogen in 492 and
two pathogens in 71 patients, accounting for 70% (563/800) of
positive urine cultures. Escherichia coli (as a single pathogen)
was the most common pathogen in positive urine cultures
(63%, 355/563), followed by Klebsiella species (7%, 39/563).
Staphylococcus species was cultured in nine patients (2%),
namely saprophyticus (1%, 8/563) and Staphylococcus saprophyti-
cus (0.2%, 1/563). Additionally, 2% contaminated (13/800) and
28% sterile urine cultures (224/800) were obtained.
The blood culture results showed one pathogen in 224 and
two pathogens in ﬁve patients, accounting for 29% (229/800) of
cultures revealing bacteraemia. E. coli (as a single pathogen)
was cultured in 72% (164/229) and Klebsiella species in 7% (17/
229). Staphylococcus species was cultured in 10 patients:
S. aureus in 1% (3/229) and coagulase-negative staphylococci
in seven patients, which was considered as contamination.
Contaminated and sterile blood cultures were obtained in 3%
(21/800) and 69% (550/800), respectively.
Overall, 7% (57/800) of the patients had discordant culture
results. Of these patients, 28% (16/57) had a different bacterial
species in the blood culture to that in the related urine culture,
whereas 72% (41/57) had bacteraemia with a related urine
culture showing contamination or no bacterial growth (Fig. 1).
Potential risk factors (uni- and multivariate) for discordant
culture results are shown in Table 1. Blood cultures were
more often sterile in pretreated than in non-pretreated
patients (74% vs. 65%; p 0.01). Covariates associated with
discordant culture results on univariate analysis at a level of
signiﬁcance of p <0.2 were included in a multiple logistic
regression model using a forward procedure. Receiving
antibiotic therapy at the moment of presentation was the
only factor independently associated with discordant culture
results (OR, 2.06; 95% CI, 1.18–3.61). Receiving antimicrobial
treatment at the moment of presentation was associated with
a 10.1% risk of having discordant culture results, compared
with 5.4% without antimicrobial treatment (risk difference,
4.7%; 95% CI, 0.91–9.1%).
In summary, in 7% of patients uropathogens caused
bacteraemia with a pathogen that was not isolated from the
urine. Receiving antibiotic therapy at the moment of presen-
tation doubled the risk of the presence of discordant culture
results.
To our knowledge, our study has the largest sample size and
is the ﬁrst to evaluate the total, diverse population of patients
with complicated UTIs. Receiving antibiotic therapy at the
moment of hospitalization turned out to be the only indepen-
dent risk factor, which conﬁrmed the results of van Nieuw-
koop et al. [12], but disagreed with Etienne et al. [11], who
Exclusion 20 patients: 
missing culture results
1,314 hospitalized patients
with complicated UTI
820 patients providing
blood and urine culture
Exclusion 494 patients: 
239 patients only urine culture
160 patients only blood culture
93 patients no culture at all
2 patients missing data
743 patients with concordant
culture result
16 patients: 
bacteraemia with 
different pathogen
in urine culture 
800 patients with available
blood and urine culture result
57 patients with discordant
culture result
41 patients: 
bacteraemia without
bacterial growth* in
urine culture 
FIG. 1. Flowchart of patients. *Or with contamination.
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found that blood cultures were always sterile in pretreated
patients. Oral antibiotic UTI treatment may be able to sterilize
the urine, because for many antibiotics concentrations in the
urine are high, while having an insufﬁcient antimicrobial effect
at the blood level, with a resulting positive blood culture [12].
A limitation of our study is its retrospective design, and we
only included patients with a complicated UTI for whom both
urine and blood cultures had been performed. Another
limitation could be the inclusion criterion that blood and
urine had to be taken on the day of starting treatment. We
accepted that for patients admitted after 21.00, urine cultures
obtained the next day should also be included, because
obtaining a urine culture can be delayed by waiting for voiding
or catheterization. Nevertheless, this scenario represents
clinical practice, making the percentages we found still clinically
relevant.
Our observed rate of 7% discordant results was relatively
high compared with the rates varying between 0 and 5% in
other, mostly retrospective, studies in adult, non-pregnant
patients with a UTI. However, these studies were performed
in subgroups of patients [5–8,11,12]. Two studies showing a
rate of discordant results of 5% also included patients that
received antimicrobial pretreatment, but in one study only
men with acute prostatitis were evaluated [11] and in the
other only patients with a febrile UTI [12].
We recommend collecting both blood and urine cultures in
patients who receive antibiotics at the moment of hospitaliza-
tion, because this appears to have a clear added diagnostic
value. It remains to be discussed whether taking blood cultures
in other patients with complicated UTIs is warranted.
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TABLE 1. Baseline characteristics and risk factors for discordant blood culture results for 800 patients with complicated UTIa
Characteristic
Total
(n = 800)
Concordant
(n = 743)
Discordant
(n = 57)
Univariate
OR (95% CI) p
Multivariate
OR (95% CI)b p
Age, mean (SD) 63.5 (21.2) 63.1 (21.3) 67.9 (19.5) 1.13 (0.98–1.29)c 0.10
Male sex 339 (42) 314 (42) 25 (44) 1.07 (0.62–1.84) 0.81
Febrile UTId 714 (89) 662 (89) 52 (91) 1.59 (0.56–4.51) 0.38
Co-morbidity
Anye 498 (62) 461 (62) 37 (65) 1.13 (0.64–1.99) 0.67
Diabetes mellitus 183 (23) 170 (23) 13 (23) 1.00 (0.52–1.89) 0.99
Immunocompromised 95 (12) 89 (12) 6 (10) 0.87 (0.36–2.07) 0.74
Urological co-morbidity 173 (22) 157 (21) 16 (28) 1.46 (0.80–2.67) 0.22
Urinary catheter 150 (19) 138 (19) 12 (21) 1.17 (0.60–2.27) 0.64
Antibiotic therapy within past 14 days
No 462 (58) 437 (59) 25 (44) Reference 0.05f 0.04g
Yes, but ﬁnished course 51 (6) 48 (6) 3 (5) 1.09 (0.32–3.75) 0.89 1.09 (0.32–3.76) 0.89
Antibiotics at the moment 286 (36) 257 (35) 29 (51) 1.97 (1.13–3.44) 0.02 2.06 (1.18–3.61) 0.01
Internal medicine ward
(compared with urology ward)
615 (77) 567 (76) 48 (84) 1.66 (0.80–3.44) 0.17
University hospital 209 (26) 196 (26) 13 (23) 0.83 (0.44–1.56) 0.55
aMissing data in <2 patients; numbers are n (%), unless otherwise indicated.
bMultivariate OR obtained by forward regression analysis and selecting variables with p <0.2 in univariate analysis as independent covariate.
cOR per 10 years increase in age (per 1 year increase in age: OR, 1.01; 95% CI, 1.00–1.03).
dFebrile UTI included (uncomplicated) pyelonephritis, urosepsis, acute prostatitis and UTI with systemic symptoms, deﬁned as fever (temperature ≥38°C), haemodynamic
instability or delirium.
eCo-morbidity included one or more of the following diseases: cardiovascular disease, immunocompromising disease (HIV, cancer for which chemotherapy was given within the
last 3 months, or immunocompromising medication (e.g. prednisone, methotrexate, azathioprine, TNF-alpha blocker)), diabetes mellitus, urological co-morbidity (an anatomical
abnormality of the urinary tract (excluding benign prostatic hyperplasia), a history of urolithiasis or neurological urinary retention), and kidney disease.
fOverall Wald test.
gOverall p-value.
p values <.05 were considered statistically signiﬁcant.
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